{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:53:38Z","timestamp":1793235218924,"version":"4.5.0"},"reference-count":48,"publisher":"Centers for Disease Control MMWR Office","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7432a2","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:06:11Z","timestamp":1756382771000},"page":"500-507","source":"Crossref","is-referenced-by-count":83,"title":["Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2025\u201326 Influenza Season"],"prefix":"10.15585","volume":"74","author":[{"given":"Lisa A.","family":"Grohskopf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenee H.","family":"Blanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Ferdinands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien G.","family":"Dugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demetre C.","family":"Daskalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024-25 influenza season.","volume":"73","author":"Grohskopf","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R2","unstructured":"CDC. Advisory Committee on Immunization Practices grading of recommendations assessment, development, and evaluation handbook for developing evidence-based recommendations. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/acip-grade-handbook\/hcp\/table-of-contents\/index.html"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R3","unstructured":"CDC. ACIP evidence to recommendation user\u2019s guide. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https:\/\/www.cdc.gov\/acip\/media\/pdfs\/2024\/09\/ACIP-EtR-Users-Guide_October-1-2020.pdf"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R4","unstructured":"CDC. Advisory Committee on Immunization Practices: GRADE: higher dose and adjuvanted influenza vaccines for persons aged \u226565 years. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https:\/\/www.cdc.gov\/acip\/grade\/influenza-older-adults.html"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R5","unstructured":"CDC. Advisory Committee on Immunization Practices: evidence to recommendations (EtR) framework: higher dose and adjuvanted influenza vaccines for persons aged \u226565 years. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/acip\/evidence-to-recommendations\/influenza-older-adults-etr.html"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R6","unstructured":"CDC. Advisory Committee on Immunization Practices: grading of recommendations, assessment, development, and evaluation (GRADE): safety of influenza vaccines for persons with egg allergy. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/acip\/grade\/influenza-egg-allergy.html"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R7","unstructured":"CDC. Advisory Committee on Immunization Practices: evidence to recommendations (EtR) framework: safety of influenza vaccines for persons with egg allergy. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https:\/\/www.cdc.gov\/acip\/evidence-to-recommendations\/influenza-egg-allergy-etr.html"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R8","unstructured":"CDC. Advisory Committee on Immunization Practices: grading of recommendations, assessment, development, and evaluation (GRADE): higher-dose and adjuvanted influenza vaccines for solid organ transplant recipients. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/acip\/grade\/influenza-solid-organ-transplant.html"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R9","unstructured":"CDC. Advisory Committee on Immunization Practices: evidence to recommendations (EtR) framework: high-dose and adjuvanted influenza vaccines for solid organ transplant recipients. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/acip\/evidence-to-recommendations\/influenza-solid-organ-transplant-etr.html"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R10","unstructured":"Food and Drug Administration. Influenza vaccine composition for the 2025\u20132026 U.S. influenza season. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/influenza-vaccine-composition-2025-2026-us-influenza-season"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R11","unstructured":"FluMist [Package insert]. Gaithersburg, MD: MedImmune; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/flumist"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R12","unstructured":"Flublok [Package insert]. Pearl River, NY: Protein Sciences; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/flublok"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.vaccine.2014.06.052","article-title":"Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season.","volume":"33","author":"Belongia","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R14","doi-asserted-by":"publisher","first-page":"20388","DOI":"10.2807\/ese.18.05.20388-en","article-title":"Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011\/12.","volume":"18","author":"Castilla","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R15","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1093\/cid\/ciw816","article-title":"Intraseason waning of influenza vaccine protection: evidence from the US Influenza Vaccine Effectiveness Network, 2011\u201312 through 2014\u201315.","volume":"64","author":"Ferdinands","year":"2017","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1093\/cid\/ciab045","article-title":"Waning vaccine effectiveness against influenza-associated hospitalizations among adults, 2015\u20132016 to 2018\u20132019, United States Hospitalized Adult Influenza Vaccine Effectiveness Network.","volume":"73","author":"Ferdinands","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R17","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2016.21.16.30201","article-title":"I-MOVE multicentre case-control study 2010\/11 to 2014\/15: is there within-season waning of influenza type\/subtype vaccine effectiveness with increasing time since vaccination?","volume":"21","author":"Kissling","year":"2016","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R18","doi-asserted-by":"publisher","first-page":"20390","DOI":"10.2807\/ese.18.05.20390-en","article-title":"Low and decreasing vaccine effectiveness against influenza A(H3) in 2011\/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study.","volume":"18","author":"Kissling","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R19","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/ijerph18031129","article-title":"Influenza vaccine effectiveness and waning effect in hospitalized older adults. Valencia Region, Spain, 2018\/2019 season.","volume":"18","author":"Mira-Iglesias","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R20","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1016\/j.vaccine.2019.03.054","article-title":"Evaluating the effectiveness of the influenza vaccine during respiratory outbreaks in Singapore\u2019s long term care facilities, 2017.","volume":"37","author":"Ng","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R21","doi-asserted-by":"publisher","first-page":"20389","DOI":"10.2807\/ese.18.05.20389-en","article-title":"Vaccine effectiveness of 2011\/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection.","volume":"18","author":"Pebody","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1093\/jpids\/piz077","article-title":"Influenza vaccine effectiveness among children for the 2017\u20132018 season.","volume":"9","author":"Powell","year":"2020","journal-title":"J Pediatric Infect Dis Soc"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R23","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1016\/j.vaccine.2017.09.035","article-title":"Waning protection of influenza vaccination during four influenza seasons, 2011\/2012 to 2014\/2015.","volume":"35","author":"Puig-Barber\u00e0","year":"2017","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R24","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1016\/j.vaccine.2016.05.034","article-title":"Influenza vaccine effectiveness: maintained protection throughout the duration of influenza seasons 2010\u20132011 through 2013\u20132014.","volume":"34","author":"Radin","year":"2016","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1093\/cid\/ciy770","article-title":"Intraseason waning of influenza vaccine effectiveness.","volume":"68","author":"Ray","year":"2019","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R26","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1017\/S0950268820002952","article-title":"Influenza vaccine failure in the tropics: a retrospective cohort study of waning effectiveness.","volume":"148","author":"Young","year":"2020","journal-title":"Epidemiol Infect"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3390\/vaccines10060888","article-title":"Waning vaccine protection against influenza among Department of Defense adult beneficiaries in the United States, 2016\u20132017 through 2019\u20132020 influenza seasons.","volume":"10","author":"Hu","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R28","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.vaccine.2019.02.027","article-title":"Intraseason decline in influenza vaccine effectiveness during the 2016 southern hemisphere influenza season: a test-negative design study and phylogenetic assessment.","volume":"37","author":"Regan","year":"2019","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R29","doi-asserted-by":"publisher","first-page":"e1031","DOI":"10.1093\/cid\/ciac577","article-title":"Sustained within-season vaccine effectiveness against influenza-associated hospitalization in children: evidence from the New Vaccine Surveillance Network, 2015\u20132016 through 2019\u20132020.","volume":"76","author":"Sahni","year":"2023","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R30","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1016\/j.vaccine.2023.03.066","article-title":"Duration of influenza vaccine effectiveness in the elderly in Japan: a retrospective cohort study using large-scale population-based registry data.","volume":"41","author":"Uemura","year":"2023","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R31","doi-asserted-by":"publisher","first-page":"2300239","DOI":"10.2807\/1560-7917.ES.2024.29.8.2300239","article-title":"Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010\/11 to 2018\/19.","volume":"29","author":"Chung","year":"2024","journal-title":"Euro Surveill"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R32","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/14760584.2024.2331073","article-title":"Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection.","volume":"23","author":"Domnich","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R33","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/infdis\/jix632","article-title":"Duration of influenza vaccine effectiveness: a systematic review, meta-analysis, and meta-regression of test-negative design case-control studies.","volume":"217","author":"Young","year":"2018","journal-title":"J Infect Dis"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R34","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1056\/NEJMoa1401480","article-title":"Influenza vaccination of pregnant women and protection of their infants.","volume":"371","author":"Madhi","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R35","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S1473-3099(17)30252-9","article-title":"Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial.","volume":"17","author":"Steinhoff","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R36","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/S1473-3099(16)30054-8","article-title":"Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R37","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1056\/NEJMoa0708630","article-title":"Effectiveness of maternal influenza immunization in mothers and infants.","volume":"359","author":"Zaman","year":"2008","journal-title":"N Engl J Med"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/archpediatrics.2010.192","article-title":"Maternal influenza vaccination and effect on influenza virus infection in young infants.","volume":"165","author":"Eick","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R39","unstructured":"Afluria [Package insert]. Parkville, Victoria, Australia: Seqirus; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/afluria-afluria-southern-hemisphere"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R40","unstructured":"Fluzone [Package insert]. Swiftwater, PA: Sanofi Pasteur; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/fluzone-and-fluzone-high-dose"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R41","unstructured":"Fluarix [Package insert]. Dresden, Germany: GSK Biologicals; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/fluarix"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R42","unstructured":"Flucelvax [Package insert]. Holly Springs, NC: Seqirus; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/flucelvax"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R43","unstructured":"FluLaval [Package insert]. Quebec City, QC, Canada: ID Biomedical Corporation of Quebec; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/flulaval"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R44","unstructured":"Fluzone High-Dose [Package insert]. Swiftwater, PA: Sanofi Pasteur; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/fluzone-and-fluzone-high-dose"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R45","unstructured":"Fluad [Package insert]. Holly Springs, NC: Seqirus; 2025. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/fluad"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R46","unstructured":"CDC. Vaccines & immunizations: general best practices for immunization. Atlanta, GA: US Department of Health and Human Services, CDC; 2025https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-best-practices\/"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R47","unstructured":"Bandell A. FluMist self\/caregiver administration [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; April 15, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/04-bandell-influenza-508.pdf"},{"key":"key-10.15585\/mmwr.mm7432a2-202508280805-R48","unstructured":"Folegatti P. Immunogenicity and safety of quadrivalent recombinant influenza vaccine (RIV4) in children and adolescents aged 9 to 17 years and adults aged 18 to 49 years [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; June 26, 2025. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-06-25-26\/02-folegatti-influenza-508.pdf"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:06:14Z","timestamp":1756382774000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7432a2.htm?s_cid=mm7432a2_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":48,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2025,8,28]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7432a2","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,28]]},"published":{"date-parts":[[2025,8,28]]}}}